ERBB3 and non-small cell lung carcinoma: In a phase I dose escalation trial for EGFR TKI-pretreated metastatic NSCLC, HER3-Dxd (5.6 mg/kg Q3W) was well tolerated with a 39% ORR and median PFS of 8.2% (NCT03260491) [127].